Abbott Laboratories
Abbott Park, IL 60064
Abbott Announces Health Canada Authorization Under the COVID-19 Interim Order and Immediate Availability of its COVID-19 Antibody Test in Canada
- New antibody blood test will run on Abbott's ARCHITECT® i1000SR and i2000SR laboratory-based instruments and will expand to its Alinity™ i system. - Abbott expects to begin shipping antibody tests to Canada this week and intends to distribute 30 million tests globally by the end of June. Abbott is already providing its COVID-19 molecular test for its m2000™ instrument in Canada. -...
Read More »
Diagnostic Tool captures 5 optical measurements.
Using advanced wavefront sensing technology, iDesign Dx measures and maps eyes with visual irregularities. System can capture shape of cornea, its curvature/power, ocular wavefront, refraction, and pupil diameter under different light conditions – all with one 3-second scan of eye. Obtaining these measurements enables ophthalmologists to screen patients to determine if they are eligible for...
Read More »Abbott Receives FDA Clearance for FreeStyle Precision Pro Blood Glucose and Beta-Ketone Monitoring System(TM)
Only inpatient blood glucose monitoring system among leading hospital brands to use individually foil-wrapped test strips, helping reduce risk of test strip cross-contamination ABBOTT PARK, Ill.- -- Abbott (NYSE: ABT) today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its FreeStyle Precision Pro Blood Glucose and Beta-Ketone Monitoring System™, an...
Read More »Modular Laboratory Automation System accelerates testing.
Consolidating multiple analytical instruments into unified workstation, ACCELERATOR-® a3600 automates pre- and post-analytical processing, sample-handling, and processing. Laboratory automation track system can process up to 3,600 samples/hr and handle multiple tube sizes and types simultaneously. Through communication connections among automation system, analyzers, and LIS or middleware,...
Read More »Molecular Diagnostic System speeds identification of pathogens.
Suited for detecting and characterizing wide range of pathogens, PLEX-ID system can detect microbes such as bacteria, viruses, and fungi in research applications. It simultaneously identifies and recognizes emerging organisms by combining polymerase chain reaction and mass spectrometry analysis. Based on Ibis T5000(TM) Biosensor System, it provides results in 6-7 hr and is suitable for...
Read More »Diagnostic Instrument automates immunoassay analysis.
ARCHITECT c4000 performs diagnostic tests that monitor general health, including levels of sodium, potassium, chloride, and organ function in patients. Then this clinical chemistry analyzer integrates with i1000SR immunoassay analyzer, it forms ARCHITECT ci4100(TM) - automated analyzer that completes immunoassay and chemistry tests on one platform. While c4000 analyzer generates up to 800 test...
Read More »Immunochemistry Analyzer boosts laboratory productivity.
Designed for labs that typically perform less than 200 immunoassay tests per day, ARCHITECT-® i1000SR-® provides continuous access to reagents and samples while it is running. Unit can accommodate 65 patient samples and process up to 100 tests/hr. It is able to prioritize emergency test results and turn them around in less than 16 min. To facilitate training of new laboratory personnel,...
Read More »Abbott Announces New Products, Data and Positive Initiatives at 2007 AACC Annual Meeting
Highlights Include Introduction of More than 40 New Assays, 12 New Systems and Expansion of 'Labs Are Vital(TM)' Initiative SAN DIEGO, July 18 - Expanding on its growing leadership position in the diagnostics market, Abbott today announced several new product launches and initiatives at the American Association of Clinical Chemistry (AACC) Annual Meeting, being held here from July 15-19. We are...
Read More »Private-Label Version of Abbott's XIENCE(TM) V Drug-Eluting Coronary Stent System Launches in Europe
ABBOTT PARK, Ill., Jan. 11 -- A private-label version of Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent System has launched in Europe, Boston Scientific Corporation announced today. The PROMUS(TM) Everolimus-Eluting Coronary Stent System is designed, studied and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies...
Read More »Abbott's HUMIRA® (adalimumab) Receives FDA Approval for Inhibiting Structural Joint Damage and Improving Physical Function in Patients with Psoriatic Arthritis
Study Results Showed HUMIRA Inhibited the Progression of Structural Joint Damage in 86 Percent of Psoriatic Arthritis Patients at 48 Weeks ABBOTT PARK, Ill., Nov. 14 // -- Abbott announced today that the U.S. Food and Drug Administration (FDA) approved an expanded indication for HUMIRA(R) (adalimumab) that includes inhibiting structural joint damage and improving physical function in patients...
Read More »
Abbott Announces Health Canada Authorization Under the COVID-19 Interim Order and Immediate Availability of its COVID-19 Antibody Test in Canada
- New antibody blood test will run on Abbott's ARCHITECT® i1000SR and i2000SR laboratory-based instruments and will expand to its Alinity™ i system. - Abbott expects to begin shipping antibody tests to Canada this week and intends to distribute 30 million tests globally by the end of June. Abbott is already providing its COVID-19 molecular test for its m2000™ instrument in Canada. -...
Read More »Abbott Completes Acquisition of Tendyne Holdings, Inc.
ABBOTT PARK, Ill. - Abbott (NYSE: ABT) announced today that it has completed its acquisition of Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies. Abbott acquired the equity of Tendyne that it did not already own for $225 million upfront, resulting in a total transaction value of $250 million, plus potential future...
Read More »Abbott to Broaden Foundation in Structural Heart Therapies with Two Mitral Valve Transactions
• Acquisition of Tendyne Holdings, Inc. to Expand Abbott's Mitral Valve Therapies • In Separate Transaction, Abbott Has Provided Capital and Secured an Option to Purchase Cephea Valve Technologies ABBOTT PARK, Ill. - Abbott (NYSE: ABT) announced today that it has entered into an agreement to purchase Tendyne Holdings, Inc., a private medical device company focused on developing minimally...
Read More »
Diagnostic Tool captures 5 optical measurements.
Using advanced wavefront sensing technology, iDesign Dx measures and maps eyes with visual irregularities. System can capture shape of cornea, its curvature/power, ocular wavefront, refraction, and pupil diameter under different light conditions – all with one 3-second scan of eye. Obtaining these measurements enables ophthalmologists to screen patients to determine if they are eligible for...
Read More »Abbott Receives FDA Clearance for FreeStyle Precision Pro Blood Glucose and Beta-Ketone Monitoring System(TM)
Only inpatient blood glucose monitoring system among leading hospital brands to use individually foil-wrapped test strips, helping reduce risk of test strip cross-contamination ABBOTT PARK, Ill.- -- Abbott (NYSE: ABT) today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its FreeStyle Precision Pro Blood Glucose and Beta-Ketone Monitoring System™, an...
Read More »Modular Laboratory Automation System accelerates testing.
Consolidating multiple analytical instruments into unified workstation, ACCELERATOR-® a3600 automates pre- and post-analytical processing, sample-handling, and processing. Laboratory automation track system can process up to 3,600 samples/hr and handle multiple tube sizes and types simultaneously. Through communication connections among automation system, analyzers, and LIS or middleware,...
Read More »Abbott to Present at RBC Capital Markets' Healthcare Conference
ABBOTT PARK, Ill., Feb. 15, 2011 -- Abbott (NYSE: ABT) will present at the 2011 RBC Capital Markets' Healthcare Conference on Thursday, March 3, 2011. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a presentation on the company at 10 a.m. Central time. A live audio webcast of the presentation will be accessible through Abbott's Investor Relations Web...
Read More »Molecular Diagnostic System speeds identification of pathogens.
Suited for detecting and characterizing wide range of pathogens, PLEX-ID system can detect microbes such as bacteria, viruses, and fungi in research applications. It simultaneously identifies and recognizes emerging organisms by combining polymerase chain reaction and mass spectrometry analysis. Based on Ibis T5000(TM) Biosensor System, it provides results in 6-7 hr and is suitable for...
Read More »Diagnostic Instrument automates immunoassay analysis.
ARCHITECT c4000 performs diagnostic tests that monitor general health, including levels of sodium, potassium, chloride, and organ function in patients. Then this clinical chemistry analyzer integrates with i1000SR immunoassay analyzer, it forms ARCHITECT ci4100(TM) - automated analyzer that completes immunoassay and chemistry tests on one platform. While c4000 analyzer generates up to 800 test...
Read More »Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review
ABBOTT PARK, Ill., Feb. 6 -- Abbott (NYSE:ABT) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) applicable to Abbott's cash tender offer to purchase all of the outstanding shares of common stock of Advanced Medical Optics (AMO) expired last night at 11:59 p.m. Eastern time. The expiration of the HSR waiting period satisfies one of the...
Read More »